Locust Walk Insights

LOCUST WALK INSIGHTS

Looking at Deal Value Beyond the Headlines

The press release is the public’s first (and oftentimes only) view into the details of a transaction.  However, while the press release is the victory lap of a transaction process, it rarely  provides the full details of the transaction.  Sure, it provides basic...

Companies are bought, because they are sold

Every entrepreneur hopes that if they build it, someday someone will come knocking at their door with a large check. But what does it take to get someone to knock on that door? And, how do you make sure your caller actually has a large check? Selling. Companies are...

Almost five years in the making…

The arrival of new regulations in the EU has been one of the hottest topics in the medical device space over the past several years.  They were first proposed in 2012 and are finally here in 2017.  The new regulations were aimed at three main goals: Improve the...

Finding the Right Partner

You’re ready to sell. Term sheets are on the table. Deal structure, terms, and timing are being highly scrutinized and negotiated back and forth. In determining the optimal deal, however, something that isn’t clearly delineated in term sheets might be the largest...

Biotalk, Episode 3: Roger Longman, Real Endpoints

In this episode of BioTalk, Locust Walk’s Vice President, Josh Hamermesh, spoke to Roger Longman, CEO of Real Endpoints, about the pricing and reimbursement issues that are affecting the biopharmaceutical industry, with a particular focus on the impact on deal making....

Q1 2017 Trends in Biotech Finance

Our Q1 report analyzes current trends of 2017, and how life science strategic deal activity has been performing in recent years. In this report you can find an overview and analysis of: Biopharma public indices Biopharma IPOs Deal activity for strategic partnership...

Deal Strategy and Objectives

The cornerstone to a successful negotiation is strong internal alignment on the objectives and structure for a deal. More often than not, companies will enter into a negotiation process in a reactionary position and gloss over, or skip entirely, the internal...

Biotalk Episode 2: Bradley Campbell, Amicus Therapeutics

In this episode of Biotalk podcast, Josh Hamermesh, Vice President of Locust Walk interviews Bradley Campbell, President & COO of Amicus Therapeutics. Amicus is very much at the forefront developing and commercializing important therapies to treat a range of...

Life is Long, Don’t Give Up

I recently had the pleasure to conduct a podcast conversation with Bradley Campbell, who is the President and Chief Operating Officer of Amicus Therapeutics (listen to the podcast here). Bradley recounted the interesting history of Amicus’ development of Galafold™...

The Potential Impact of FDA Leadership Changes on Drug Partnership

With the election of President Trump and a Republican congress last November, many (including Locust Walk) have speculated on the future of pricing, reimbursement, drug approval and other potential policy changes and their potential impact on the biopharma industry....

What happened to the value of priority review vouchers (PRV)?

The FDA Amendments Act of 2007 created an incentive system for drug developers to pursue tropical neglected diseases, whereby upon approval of a product for a designated tropical disease, the drug developer would receive a voucher that could be applied to receive a...

Immunomedics and venBio: Activist Investors in Biotech

This has certainly been an eventful few months for Immunomedics and its largest shareholder, venBio.  In case you haven’t been following, below is a brief replay: Towards the end of last year, venBio, the beneficial owner of approximately 9.9% of the outstanding...